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Tuberculosis (TB) remains a disease of global importance with 
approximately two million deaths annually worldwide. Effective 
treatment of TB has been hampered by the emergence of drug 
resistant strains of Mycobacterium tuberculosis. Natural products 
have a proven global history of treating TB diseases and ailments. 
Available vast reservoir of chemically diverse natural products that 
provide new templates for drug design can be scrutinized and the 
most efficient may be chosen by molecular docking studies with the 
TB proteins. In the present study, an attempt has been made to find 
out a potential natural product to inhibit M. tuberculosis – protein 
kinase B (PknB) protein by molecular docking method. Docking 
has been performed for around 40 natural products against  
M. tuberculosis – PknB protein target to determine their potentiality 
against TB diseases. The anti-TB ability has been analysed in terms 
of binding energy. The results indicate that 80% of the natural 
products (B.E ≥ -7 kcal/mol) under study, exhibit good anti-TB 
activity. It is known that most of the natural product under study is 
found to possess greater binding activity than that of the 
conventional anti-TB drugs.  
Keywords: Anti-TB agents, Molecular docking, Protein kinase 
B (PKnB) Protein 
Tuberculosis (TB) is an infectious disease and is 
caused by the bacterium Mycobacterium tuberculosis. 
TB generally affects the lungs, but can also affect 
other parts of the body. In recent years, researchers 
have revealed that the M. tuberculosis, which is the 
causative agent of TB, is getting resistant towards 
conventional drugs used for the treatment. The 
developments of drug resistant in M. tuberculosis 
have frightened the global health community. 
Multidrug-resistant tuberculosis (MDR-TB) is a 
condition where the M. tuberculosis strain is resistant 
to the two most frequently used first-line oral drugs 
specifically Isoniazid and Rifampicin. Development of 
new drugs in the field of TB continues to be more 
challenging because of the emergence of drug 
resistance organisms. However, synthetic drugs such as 
Nitroimidazoles (PA-824 & PA-1343), 
Nitroimidazooxazoles (OPC-67683), Diarylquinoline 
TMC-207(R207910) Oxazolidinones (Linezolid,  
DA - 7157 and RBX8700), Ethylene diamine SQ - 
109, Pyrrole derivatives (BM212 & LL3858), 
Phenazines (B4128 & B4169), 2’–monosubstituted 
Isoniazid derivatives etc., are currently in clinical 
phase studies1. Most of the TB drugs have side effects 
and are also costly. Hence, research on anti TB drug 
discovery to find new therapy than the existing one, to 
develop novel and potentially anti TB drug that would 
significantly reduce the treatment time and to combat 
MDR and XDR-TB becomes more challenging. In 
parallel, there is an increasing inclination towards the 
use of an alternative source of medicine, especially 
based on the medicinal plants. It is noteworthy that 
one of the ancient medical practice of India called as 
Ayurveda (Ayur = Life, Veda = Science), defines 
more than 250 medicinal plants for treating  
TB disease2,3. Medicinal plants that possess  
anti-mycobacterial activity against MDR-TB have 
also been reported across the globe4-7. And also, the 
medicinal plants that are found to be 
antimycobacterially active were ethno medically used 
for the treatment of tuberculosis or related symptoms 
such as cough and other respiratory diseases8,9. But, it 
is tedious to determine the most potential 
antimycobacterial medicinal plant by analysing and 
comparing the efficacy of vastly available medicinal 
plant samples by experimental evaluation. But 
nowadays, bioinformatics have opened a new horizon 
in the field of drug discovery. Molecular docking is 
used to predict the binding orientation and binding 
affinity of a particular chemical component with the 
target protein. Thus, interfacing docking 
methodologies with the knowledge of natural 
products may pave way to investigate the potential 
anti-TB drugs. Therefore, in the present work, we 
sought to screen some of the natural products for their 
anti-TB property by docking them with  
M. tuberculosis – protein kinase B (PknB) protein 
target.  
 Actually, genome of M. tuberculosis codes for 
about 4000 proteins. M. tuberculosis pathogen 
requires an efficient way of sensing and transducting 
extracellular signals to adapt to the changing 
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environmental conditions10. For cell signals, the 
regulation of cell growth and cell division involving 
the reversible phosphorylation on Serine/Theronine 
residues are critical in the bacterium11. Hence, kinases 
are attractive drug targets due to the range of crucial 
cellular processes in which they are involved.  
M. tuberculosis – (PknB) is an essential receptor like 
protein kinase involved in cell growth control. It is a 
transmembrane Ser/Thr protein kinase and can be 
considered as a suitable drug target for tuberculosis12. 
PknB is predicted to consist of 626 amino acids with a 
transmembrane segment dividing the protein into an  
N-terminal intracellular domain and a C-terminal 
extracellular domain. The N-terminal of PknB 
includes a kinase domain and juxtamembrane linker 
of 52 residues13. And also, infection studies with a 
mouse model reveal that depletion of PknB results in 
clearance of pathogens from the host tissues, 
indicating definitively that PknB is essential for 
survival of the pathogen within the host14. Although 
docking studies of natural products with M. tb 
proteins are enormous, there are limited or no studies 
related to docking with M. tuberculosis – PknB 
protein. Thus, PknB is chosen as the drug target in the 
present study. It was hoped that the present study, 
being the first to identify a good natural inhibitor for 
PknB target and a potential lead natural product 
against the TB. The study will highlight the efficacy 
of the chosen natural products as potent anti-TB 
agents from their calculated binding energies with the 
target protein and by comparison of that with the 
binding energies of conventional drugs recommended 
for the treatment of various forms of tuberculosis. 
Computational details 
 Ligand and Protein Preparation 
Natural products chosen for this work were selected 
from literature sources. For each compound, a 
molecular structure file was generated by using 
Chemsketch15. The crystal structure of the protein 
(PDB ID: 2fum) was retrieved from the Protein Data 
Bank. All the bound substances (ligand and co-factors) 
and solvent molecules were removed from the protein 
molecule. Docking experiment was performed for the 
natural products against PknB protein using Auto Dock 
4.016,17. The Lamarkian Genetic Algorithm was used 
during the docking process to explore the best 
conformational space for the ligand. The other 
parameters were set as default. The ligand binding 
domain of target protein PknB was predicted using the 
Site Finder module of Molecular Operating 
Environment. UCSF Chimera software18 is used to 
visualize the best docked conformations and hydrogen 
bonding interactions. 
 
Results and Discussion 
 Natural products as Ligands  
A set of 40 natural products that are found to obey 
Lipinski’s rule have been chosen for the docking 
analysis (Table 1) and their corresponding structures 
are presented in Supplementary data, Table S1.  
 
Drug-like properties 
In silico profiling of all the natural products under 
study to predict their drug-like properties, as 
summerised in Lipinski’s “Rule of Five” (for orally 
administered drugs, which have molecular weight  
(M. W.) ≤ 500, Clog P ≤ 5, H-bond donors (HBD) ≤ 5 
Table 1 ⸺ Drug-like properties of the natural products chosen for the study and calculated binding energies of natural products to target 
protein PknB of M. tuberculosis—(Contd.) 
S.  
No. 
Natural Products Botanical & (Family) 
name 
M.W. No of H–bond 
donor 
No. of H–bond 
acceptor 
No. of rotatable 
bonds 
M.R. cm3 B.E. 
(kcal/mol)
1 Allin Allium sativum 
(Lilliaceae) 
177.22 3 4 5 43.49 ± 0.3 –4.42 
2 Gallic acid Allium sativum 
(Lilliaceae) 
170.12 4 5 1 38.82  ± 0.3 –4.85 
2 α –Pinene Rosmarinus officinalis 
(Lamiaceae) 
136.23 0 0 0 43.96 ± 0.3 –5.20 
4 Coumarin Dipteryx odorata 
(Fabaceae) 
146.14 0 2 0 39.76 ± 0.3 –5.57 
5 Farnesol Vachellia farnesiana 
(Fabaceae) 
222.37 1 1 7 72.77 ± 0.3 –5.60 
6 1,4- Naphthoquinone Juglans nigra 
(Juglandaceae) 
158.15 0 2 0 42.90 ± 0.3 –5.86 
7 Chelerythrine Chelidonium majus 
(Papaveraceae) 
348.37 0 5 2 - –6.15 
(Contd.)
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Table 1 ⸺ Drug-like properties of the natural products chosen for the study and calculated binding energies of natural products to target 
protein PknB of M. tuberculosis—(Contd.) 
S.  
No. 
Natural Products Botanical & (Family) 
name 
M.W. No of H–bond 
donor 
No. of H–bond 
acceptor 
No. of rotatable 
bonds 
M.R. cm3 B.E. 
(kcal/mol)
8 Methazolamide Punica granatum 
(Lythraceae) 
236.27 2 7 2 53.06 ± 0.5 –6.26 
9 Andrographolide Andrographis paniculata
(Acanthaceae) 
350.45 3 5 3 94.13 ± 0.4 –6.48 
10 Abruquinone B Abrus precatorius 
(Fabaceae) 
390.38 0 8 6 97.26 ± 0.4 –6.73 
11 Acetazolamide Punica granatum 
(Lythraceae) 
222.25 3 7 2 45.95 ± 0.4 –6.81 
12 Plumbagin Plumbago zeylanica 
(Plumbaginaceae) 
188.18 1 3 0 49.49 ± 0.3 –6.90 
13 Xanthone Canscora decussata 
(Gentianaceae) 
196.2 0 2 0 55.53 ± 0.3 –7.04 
14 Sparsiflorine Croton sparsiflorus 
(Euphorbiaceae) 
283.32 3 4 1 79.61 ± 0.3 –7.47 
15 Aristolactum Piper nigrum 
(Piperaceae) 
341.27 1 8 3 88.25 ± 0.3 –7.58 
16 Quindoline Crytolepis sanguinolenta
(Apocyanaceae) 
218.25 1 2 0 72. 30 ± 0.3 –7.59 
17 Graveolinine Ruta graveolens  
(Rutaceae) 
279.29 0 4 2 79.61 ± 0.3 –7.66 
18 Cryptolepine Cryptolepis sanguinolenta
(Apocyanaceae) 
232.28 0 2 0 72.30 ± 0.5 –7.90 
19 Plumericin Plumeria bicolor  
(Apocynaceae) 
290.27 0 6 2 69.72 ± 0.4 –7.95 
20 Pachypodol Agastache rugosa 
 (Lamiaceae) 
344.31 2 7 4 86.77 ± 0.4 –8.04 
21 Crotsparine Croton sparsiflorus 
(Euphorbiaceae) 
283.32 2 4 1 78.38 ± 0.4 –8.11 
22 Kaempferol Acalypha indica 
(Euphorbiaceae) 
286.24 4 6 1 71.43 ± 0.3 –8.13 
23 Obtusifoliol Acacia obtusifolia 
(Aristolochiaceae) 
426.72 1 1 5 133.00 ± 0.4 –8.13 
24 Diosyprin Diospyros montana 
(Ebenaceae) 
374.34 2 6 1 97.40 ± 0.3 –8.17 
25 Piperine Piper nigrum 
(Piperaceae) 
285.34 0 4 3 82.14 ± 0.3 –8.26 
26 Pinostrobin Cajanus cajan 
(Fabaceae) 
270.28 1 4 2 - –8.26 
27 Luteolin-7-o-
glucoside 
Gentianopsis paludosa 
(Gentianaceae) 
286.24 4 6 1 71.73 ± 0.3 –8.34 
28 Homoeriodictyol Eridictyon californium 
(Boranginaceae) 
302.28 3 6 2 76.93 ± 0.3 –8.35 
29 Tangeretin Citrus reticulate 
(Rutaceae) 
372.37 0 7 6 97.59 ± 0.3 –8.49 
30 Berberine Berberis aristata 
(Beriberidaceae) 
336.36 0 5 2 - –8.55 
31 Rhamnetin Syzygium aromaticum 
(Myrtaceae) 
316.26 4 7 2 78.11 ± 0.3 –8.62 
32 Eriodictyol Citrus limon 
(Rutaceae) 
288.25 4 6 1 72.13 ± 0.3 –8.78 
33 Fisetin Cotinus coggygria 
(Anacardiaceae) 
288.24 4 6 1 71.43 ± 0.3 –8.81 
        (Contd.)
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and acceptors (HBA) ≤ 10), was performed, and the 
details are presented in Table 119. The entire natural 
product chosen for the current study had a molecular 
weight less than 500. 
 
Docking calculations 
Docking studies are widely used methods in lead 
discovery because it is advantageous in the elimination 
of undesired molecules from compound libraries and the 
reduction of cost and time in drug discovery projects. In 
the current research work, docking method is used to 
predict the binding efficacy of the chosen natural 
compounds with PknB protein. 
The chosen 40 natural products were docked with the 
anti-TB target protein (PknB), to predict their binding 
energies and possible binding modes using Autodock 
tools16,17. The three dimensional structure of the receptor 
protein – PknB is represented in the Fig. 1. The best 
docked conformations were selected, visualized, and 
analyzed using Autodock tools16,17 and Chimera 
softwares18. The interaction of the ligands with the active 
site residues of the target PknB was analysed in terms of 
the binding energy, number of hydrogen bonds 
established by the ligand with residues of the active site. 
Autodock uses the following empirical formula to 
calculate the Free energy of binding: 
 
Binding energy (∆G) = Intermolecular energy + 
(vanderWaal’s hydrogen bond desolvation energy + 
Electrostatic energy) + Total internal energy + 
Torsional energy – Unbound energy of the system 
 
The dock score of Autodock is reported in 
kcal/mol. The calculated binding energies of all the 
natural products under study are presented in the 
Table 1. The conventional anti-TB drugs such as 
Isoniazid, Pyrazinamide and Ethambutol are also 
docked with the same target protein to deliberate the 
anti-TB ability of the natural products chosen for the 
study and are presented in the Table 2.  
The best docking score (free energy with a more 
negative value) indicates the highest ligand–protein 
affinity. A closer look of the docked binding energies 
of all the natural products under study in Table 1 
revealed that 80% of the chosen natural compounds 
have good binding affinities (BE ≥ –7 kcal/mol) with 
the selected target protein. From the Table 1 and 2, it 
is known that most of the natural products under study 
were found to possess greater binding ability than that 
of the anti-TB drugs considered for the comparison 
purpose. The results indicate that the natural products 
are better to treat the TB disease when compared to 
the synthetic drug having severe side effects.  
Among the natural products under study, the top 
lead molecules with best binding affinity are Stipulin 
(B.E. ~ –10.41 kcal/mol), Sobachalcone, (B.E. ~ –9.62 
kcal/mol), Isohamnetin, (B.E. ~ –9.18 kcal/mol), 
Aromadendrine (BE ~ –9.07 kcal/mol) and Quercetin, 
(B.E ~ –9.04 kcal/mol). These top lead molecules are 
analyzed further, in terms of the parameters such as 
number of hydrogen bonds established by the ligand 
with the residues of the active site and conformations 
oriented by the ligand within the active site (Table 3). It 
is known that desolvation energy is a prime parameter 
that decides a molecular interaction with its 
pharmacodynamic target and it is found to be good for 
all the top lead molecules (Table 3). In the biological 
environment, all the drug binding pockets of a target 
protein remain solvated and hence a ligand cannot as 
such occupy the active site unless it dislodges the water 
molecules.  
Table 1 ⸺ Drug-like properties of the natural products chosen for the study and calculated binding energies of natural products to target 
protein PknB of M. tuberculosis—(Contd.) 
34 Emodin Ventilago maderaspatana 
(Rhamnaceae) 
270.24 3 5 0 69.13 ± 0.3 –8.98 
35 Quercetine Allium cepa 
(Liliaceae) 
302.24 5 7 1 73.31 ± 0.3 –9.04 
36 Aromadendrin Pinus sibirica 
(Pinaceae) 
288.25 4 6 1 71.84 ± 0.3 –9.07 
37 Aloe emodin Aloe barbadensis miller 
(Asphodelaceae) 
270.24 3 5 0 69.13 ± 0.3 –9.13 
38 Isorhamnetin Brassica nigra 
(Brassicaceae) 
316.26 4 7 2 78.11 ± 0.3 –9.18 
39 Sobachalcone Dorstenia barteri  
(Moraceae) 
324.37 3 4 5 96.10 ± 0.3 –9.62 
40 Stilpulin Dalbergia stipulacea  
(Fabaceae) 
392.49 3 4 7 119.45 ± 0.3 –10.41 
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The top lead molecules with its most likely binding 
conformation are docked into the binding cavity of 
the receptor and the intermolecular interactions  
(H–bonds) are identified. The identified hydrogen 
bonding interactions between the ligand and the 
protein was illustrated in the Fig. 1 (a–f). For all the 
top lead molecules, the bond conformation was 
stabilized by strong interactions with polar and non-
polar side chains of the amino acids in the binding 
pockets owing to the presence of hydrogen bond 
donors in them. Stipulin is anchored by four hydrogen 
bonds with amino acid residues such as Tyr94, Tyr75, 
Asp96 and Asp36 of the active site of PknB protein. 
Sobachalcone interacted with Tyr94, Tyr75, Tyr94, 
Asp96, Thr149 and Ser147, by forming seven 
hydrogen bonds and Aromadendrin established five 
H–bonds with Glu93, Val95 and Asp156, of the 
active site of PknB protein. Isohamnetin forms five 
H–bonds with the amino acid residues such as Asp 
156, Val 95, Glu 93, Gly 97 and Aloe emodin 
interacted by forming four hydrogen bonds with Val 
95, Asp 156, Glu 93, of the active site of PknB 
protein. Quercetine established six H – bonds with the 
amino acid residues such as Val 95, Asp 156, Gly 96, 
Glu 93 of the active site of PknB protein. In addition 
to the usual medicinal uses of all the lead compounds, 
the results of our docking study support the fact that 
they also possess a greater binding affinity towards 
the PknB protein and hence have greater potential to 
combat the TB disease. But, further in vitro 
investigation is necessary to confirm their actual 
  
Fig. 1 ⸺ The ligand with its most likely binding conformation is docked into the binding cavity of the receptor and the intermolecular
interactions (H-bonds) are identified (a–f). 
 
Table 2 ⸺ Predicted binding energies of known anti-TB drugs to 
target protein PknB of M. tuberculosis 
S. No. Conventional 
anti-TB drugs 
Binding Energies* 
(kcal/mol) 
Binding Energies 
(kcal/mol) 
1 Isoniazid –4.0 –4.71 
2 Pyrazinamide –3.9 –4.01 
3 Ethambutol –3.7 –2.14 
*The binding energies of the drugs calculated using Autodock Vina20
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therapeutic efficacy and drug ability towards the 
disease.  
 
Conclusions 
Literature reports revealed a large set of natural 
products having anti TB properties, but their isolation, 
structural characterization and experimental 
evaluation of their medicinal properties are normally 
time-consuming, difficult and expensive. To meet the 
demanding challenge of simplifying the process, 
molecular docking studies help to chart, navigate, and 
analyze systematically the chemical space of huge 
natural products for drug discovery. The results of this 
in silico study indicate that 80% of the natural 
products (B.E. ≥ -7 kcal/mol) under study, exhibit 
greater binding activity than that of the conventional 
anti-TB drugs. The current work suggests that 80% of 
the natural products under study have the unique 
capability to counter the deadly tuberculosis pathogen 
by binding strongly to the PknB protein of it. Though 
the natural products under study are structurally 
diverse, they may be considered as the useful 
templates for the discovery of new pharmaceuticals 
for the treatment of tuberculosis, but further in vitro 
investigation is needed to confirm their authentic 
healing prospective towards the disease.  
Supplementary data 
Supplementary data associated with this  
article are available in the electronic form at: 
http://nopr.niscair.res.in/jinfo/ijca/IJCA_59A(02)207-
213_SupplData.pdf. 
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